N-异丙基甘氨酸 | 3183-21-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-异丙基甘氨酸
• 英文名称: 2-(2-propylamino)acetic acid
• 英文别名: N-Isopropylglycin；N-isopropyl-glycine；N-isopropylamino acetic acid；2-(isopropylamino)acetic acid；2-(Propan-2-ylazaniumyl)acetate
• CAS: 3183-21-9
• 化学式: C₅H₁₁NO₂
• mdl: MFCD06208781
• 分子量: 117.148
• InChiKey: HEPOIJKOXBKKNJ-UHFFFAOYSA-N

物化性质

• 熔点：
  193-195 °C (decomp)
• 沸点：
  201.3±23.0 °C(Predicted)
• 密度：
  1.019±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  N-异丙基甘氨酸 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3,4-dichlorophenyl)-N'-(1-isopropyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)guanidine
  参考文献：
  名称：

  Synthesis and Antimalarial Activity of 2-Guanidino-4-oxoimidazoline Derivatives

  摘要：

  A series of 2-guanidino-4-oxoimidazoline (deoxo-IZ) derivatives was prepared and showed potent antimalarial activities in rodent and Rhesus models. Compound 8e, the most potent analogues of this series, is the first non-8-aminoqinoline antimalarial that demonstrated radical curative activity in non-human primate by Cl oral route and showed causal prophylactic activity comparable to that of the commonly used clinical drugs in Rhesus monkeys infected with sporozoites of Plasmodium cynomolgi. The metabolic stability and metabolites profile indicated that the new deoxo-IZ derivatives (8) may act as prodrugs of the corresponding IZ (1 and 2) derivatives.

  DOI：

  10.1021/jm200111g
• 作为产物：
  描述：

  2-(异丙基氨)乙醇 在 (^tBuPNN)Ru(CO)HCl 、 水 、 sodium hydroxide 、 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 24.0h， 以87%的产率得到N-异丙基甘氨酸
  参考文献：
  名称：

  氨基醇和碱性放水H2氨基酸盐的一般合成

  摘要：

  开发了一种原子经济且环境友好的方法，仅使用碱性水将氨基醇转化为氨基酸盐，无需预保护或添加氧化剂，由钌钳络合物催化。水是溶剂，是羧酸基团氧原子的来源，也是真正的氧化剂，释放出二氢。通过应用这种新方法，可以以极好的收率生产许多重要且有用的天然和非天然氨基酸盐。

  DOI：

  10.1021/jacs.6b03488

文献信息

• Highly active bidentate N-heterocyclic carbene/ruthenium complexes performing dehydrogenative coupling of alcohols and hydroxides in open air
  作者：Zhi-Qin Wang、Xiao-Sheng Tang、Zhao-Qi Yang、Bao-Yi Yu、Hua-Jing Wang、Wei Sang、Ye Yuan、Cheng Chen、Francis Verpoort

  DOI：10.1039/c9cc03519b

  日期：——

  Eight bidentate NHC/Ru complexes, namely [Ru]-1–[Ru]-8, were designed and prepared. In particular, [Ru]-2 displayed extraordinary performance even in open air for the dehydrogenative coupling of alcohols and hydroxides. Notably, an unprecedentedly low catalyst loading of 250 ppm and the highest TON of 32 800 and TOF of 3200 until now were obtained.

  设计并制备了八种双齿NHC / Ru络合物，即[Ru] -1– [Ru] -8。尤其是，Ru-2在醇和氢氧化物的脱氢偶联中甚至在露天中也表现出非凡的性能。值得注意的是，迄今为止获得了前所未有的低催化剂负载量250 ppm和最高TON 32800和TOF 3200。
• Benzimidazolones and analogues
  申请人：American Home Products Corporation

  公开号：US06380235B1

  公开（公告）日：2002-04-30

  The present invention provides compounds and pharmaceutical formulations useful as progesterone receptor agonists and antagonists and having the general formula: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R5 are independently selected from H or optionally substituted C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alknyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4 and R5 to from a 5 to 7 membered ring; R1 is selected from H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, substituted alknyl, —COH, or optionally substituted —CO(C1 to C3 alkyl), —CO(aryl), —CO(C1 to C3 alkoxy), or —CO(C1 to C3 aminoalkyl) groups; R2 is selected from H, halogen, CN, NO2, or optionally substituted C1 to C6 alkyl, C1 to C6 alkoxy, or C1 to C6 aminoalkyl groups; R3 is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromatic ring containing 1 or 2 substituents; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt thereof. The invention also includes methods of contraception and methods of treating or preventing maladies associated with the progesterone receptor.

  本发明提供了作为孕激素受体激动剂和拮抗剂有用的化合物和药物配方，其具有以下一般式： 其中： A为O、S或NR4； B为A和C═Q之间的键，或基团CR5R6； R4、R5、R5分别独立地选自H或可选择地取代的C1到C6烷基，C2到C6烯基，C2到C6炔基，C3到C8环烷基，取代的C3到C8环烷基，芳基或杂环基，或由融合R4和R5形成的5到7成员环的环烷基；R1选自H、OH、NH2、C1到C6烷基，取代的C1到C6烷基，C3到C6烯基，取代的C1到C6烯基，炔基，取代的炔基，—COH，或可选择地取代的—CO(C1到C3烷基)，—CO(芳基)，—CO(C1到C3烷氧基)，或—CO(C1到C3氨基烷基)基团；R2选自H、卤素、CN、NO2，或可选择地取代的C1到C6烷基，C1到C6烷氧基，或C1到C6氨基烷基基团；R3选自三取代苯环；或含有1个或2个取代基的5-或6成员杂芳环；Q为O、S、NR8或CR9R10；或其药学上可接受的盐。该发明还包括避孕方法和治疗或预防与孕激素受体相关的疾病的方法。
• Combination therapies using benzimidazolones
  申请人：American Home Products Corporation

  公开号：US06423699B1

  公开（公告）日：2002-07-23

  This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R6 are independently selected from H or optionally substituted C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alkynyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4 and R5 to from a 5 to 7 membered ring; R1 is selected from H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, substituted alkynyl, —COH, or optionally substituted —CO(C1 to C3 alkyl), —CO(aryl), —CO(C1 to C3 alkoxy), or —CO(C1 to C3 aminoalkyl) groups; R2 is selected from H, halogen, CN, NO2, or optionally substituted C1 to C6 alkyl C1 to C6 alkoxy, or C1 to C6 aminoalkyl groups; R3 is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromnatic ring containing 1 or 2 substituents; or a pharmaceutically acceptable salt thereof, in combination with a progestational agent, an estrogen, or both or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. These combinations may also be used to in methods of contraception, to stimulate food intake or for minimization of side effects or cyclic menstrual bleeding.

  这项发明涉及利用替代吲哚啉衍生物化合物的循环组合疗法和方案，这些化合物是孕激素受体拮抗剂，具有以下一般结构： 其中： A为O、S或NR4； B为A和C═Q之间的键，或基团CR5R6；R4、R5、R6分别独立地选自H或可选择取代的C1至C6烷基、C2至C6烯基、C2至C6炔基、C3至C8环烷基、取代的C3至C8环烷基、芳基或杂环基，或由R4和R5融合形成5至7成员环的环烷基；R1选自H、OH、NH2、C1至C6烷基、取代的C1至C6烷基、C3至C6烯基、取代的C1至C6烯基、炔基、取代的炔基、—COH，或可选择取代的—CO(C1至C3烷基)、—CO(芳基)、—CO(C1至C3烷氧基)或—CO(C1至C3氨基烷基)基团；R2选自H、卤素、CN、NO2，或可选择取代的C1至C6烷基、C1至C6烷氧基或C1至C6氨基烷基基团；R3选自三取代苯环；或含有1或2个取代基的5-或6成员杂芳环；或其药学上可接受的盐，与孕激素类药物、雌激素或两者结合，用于治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症、多囊卵巢综合征、子宫内膜、卵巢、乳腺、结肠、前列腺的癌瘤和腺癌。这些组合物也可用于避孕方法、刺激食欲或减少副作用或周期性月经出血。
• Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of
  申请人：American Home Products Corporation

  公开号：US05554607A1

  公开（公告）日：1996-09-10

  A method for increasing the HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration, which comprises administering to said mammal, orally or parenterally, a compound of formula I: ##STR1## wherein R is alkyl; a substituted or unsubstituted aromatic N, O or S heterocycle; substituted or unsubstituted aryl, arylalkyl, benzhydryl or indanyl, in which the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkyl or hydroxy; and R.sup.1 is aryl, alkyl, alkenyl, alkynyl or substituted aryl where the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkoxy or hydroxy.

  一种用于增加需要增加高密度脂蛋白胆固醇血浓度的哺乳动物血液中HDL胆固醇浓度的方法，包括向所述哺乳动物口服或静脉注射化合物I的步骤：##STR1##其中R为烷基；取代或未取代的芳香族N、O或S杂环；取代或未取代的芳基、芳基烷基、苯基甲基或茚基，在其中取代基是从烷基、烷氧基、烷硫基、烯基、炔基、卤素、全氟烷基、全氟烷基或羟基组成的群中独立选择的一到三个成员；以及R.sup.1为芳基、烷基、烯基、炔基或取代芳基，其中取代基是从烷基、烷氧基、烷硫基、烯基、炔基、卤素、全氟烷基、全氟烷氧基或羟基组成的群中独立选择的一到三个成员。
• 2-thioxo-imidazolidin-4-one derivatives
  申请人：American Home Products Corporation

  公开号：US05861517A1

  公开（公告）日：1999-01-19

  The compound of formula I: ##STR1## in which R.sup.1 is alkyl or alkenyl; R.sup.2 is alkyl and R.sup.3 and R.sup.4 are, independently, hydrogen or alkyl; or R.sup.2 is hydrogen and R.sup.3 and R.sup.4 taken together are ortho substituted trimethylene or tetramethylene are useful for increasing blood serum HDL levels.

  化合物的化学式为I：##STR1## 其中R.sup.1是烷基或烯基；R.sup.2是烷基，R.sup.3和R.sup.4分别是氢或烷基；或者R.sup.2是氢，R.sup.3和R.sup.4结合在一起是邻位取代的三亚甲基或四亚甲基，对增加血清中的高密度脂蛋白水平有用。